Mirum Pharmaceuticals and Incyte reported positive pivotal Phase 2 results from Cohort 1 of the PROGRESS study for investigational Zilurgisertib in patients aged 12 years and older with Fibrodysplasia Ossificans Progressiva. The data support the program's clinical advancement and improve the drug's development outlook. The readout is favorable for both companies, though the broader market impact should be limited to the shares and biotech peer group.
Mirum Pharmaceuticals and Incyte reported positive pivotal Phase 2 results from Cohort 1 of the PROGRESS study for investigational Zilurgisertib in patients aged 12 years and older with Fibrodysplasia Ossificans Progressiva. The data support the program's clinical advancement and improve the drug's development outlook. The readout is favorable for both companies, though the broader market impact should be limited to the shares and biotech peer group.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
